Post Profile

PharmaMar licenses synthetic marine-derived payloads to Seattle Genetics

(Pharmamar) PharmaMar will receive an upfront payment of 5,000,000 US dollars, followed by development milestones if an antibody-drug conjugate enters clinical development.
read more


Related Posts

Mayo Clinic Offers Zika Antibody Test via Emergency Use Authorization

Health : Newswise Medical News

Mayo Clinic will offer the Zika virus antibody test developed by the Centers for Disease Control and Prevention (CDC).This test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and has ...

Newly Engineered Monoclonal Antibody Shows Promise, Moves Toward Clinical Testing

Health : Newswise Medical News

Memorial Sloan Kettering Cancer Center and Eureka Therapeutics recently entered into a licensing agreement with Novartis to develop a unique monoclonal antibody.

Notes from ASCO: Seattle Genetics Plays With Legos

Health : Wall Street Journal Health Blog

The model of an antibody conjugate required 85,000 Legos, mostly green ones.

Immunomedics in $2 billion licensing deal with Seattle Genetics

Health : Reuters: Health

(Reuters) - Immunomedics Inc said it entered into a licensing deal for its cancer treatment with Seattle Genetics Inc for a potential payment of up to about $2 billion.

SMi's Inaugural Antibody Drug Conjugates Summit, 23-24 May 2012, London

Health : Medical News Today

Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being deliver...


Copyright © 2016 Regator, LLC